Detecting chloroquine retinopathy: Electro-oculogram versus colour vision

British Journal of Ophthalmology

Volumn 87, Issue 7, 2003, Pages 902-908

  Neubauer, Aljoscha S ^a   Samari Kermani, K ^a   Schaller, U ^a   Welge Lussen U ^a   Rudolph, G ^a   Berninger, T ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

ADULT; ARTICLE; CLINICAL EXAMINATION; COLOR VISION; COMPUTER ANALYSIS; CONTROLLED STUDY; CORNEA DISEASE; ELECTROOCULOGRAM; EYE COLOR; EYE FUNDUS; EYE TOXICITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA MACULOPATHY; RETINOPATHY; RHEUMATIC DISEASE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

AGING; ANTIRHEUMATIC AGENTS; CHLOROQUINE; COLOR PERCEPTION; CORNEA; ELECTROOCULOGRAPHY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETINAL DISEASES; VISION TESTS;

EID: 0038461034     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.7.902     Document Type: Article

References (78)

1. Cambioggi A. Unusual ocular lesions in a case of systemic lupus erythematosis. Arch Ophthalmol 1957;57:451-3.
2. Hobbs H, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478.
3. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75:25-34.
4. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin 1999;39:49-57.
5. Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990;25:249-51.
6. Francois J, Maudgal MC. Experimentally induced chloroquine retinopathy in rabbits. Am J Ophthalmol 1967;64:886-93.
7. Slowik C, Somodi S, von Gruben C, et al. [Detection of morphological corneal changes caused by chloroquine therapy using confocal in vivo microscopy.] Ophthalmologe 1997;94:147-51.
8. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85:23-9.
9. Fielder A, Graham E, Jones S, et al. Royal College of Ophthalmologists guidelines:ocular toxicity and hydroxychloroquine. Eye 1998;12(Pt 6):907-9.
10. Brinkley Jr JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979;88:1-11.
11. Mavrikakis M, Papazoglou S, Sfikakis PP, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996;55:187-9.
12. Cruess AF, Schachat AP, Nicholl J, et al. Chloroquine retinopathy. Is fluorescein angiography necessary? Ophthalmology 1985;92:1127-9.
13. Easterbrook M. The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 1984;91:1368-72.
14. Hart Jr WM, Burde RM, Johnston GP, et al. Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression. Arch Ophthalmol 1984;102:377-80.
15. Easterbrook M, Trope G. Value of Humphrey perimetry in the detection of early chloroquine retinopathy. Lens Eye Toxic Res 1989;6:255-68.
16. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy:a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
17. Vu BL, Easterbrook M, Hovis JK. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999;106:1799-803; discussion 804.
18. Kolb H. Electro-oculogram findings in patients treated with antimalarial drugs. Br J Ophthalmol 1965;49:573-89.
19. Sverak J, Erbenova Z, Peregrin J, et al. [The ERG and EOG potentials aft a long-term Resochin therapy.] Klin Monatsbl Augenheilkd 1970;157:389-92.
20. Graniewski-Wijnands HS, van Lith GH, Vijfvinkel-Bruinenga S. Ophthalmological examination of patients taking chloroquine. Doc Ophthatmol 1980;48:231-4.
21. Percival SP. The ocular toxicity of chloroquine. Trans Ophthalmol Soc UK 1967;87:355-7.
22. Reijmer CN, Tijssen JG, Kok GA, et al. Interpretation of the electro-oculogram of patients taking chloroquine. Doc Ophthalmol 1980;48:273-6.
23. Van Lith GH. Electro-ophthalmology and side-effects of drugs. Doc Ophthalmol 1977;44:19-21.
24. Pinckers A, Broekhuyse RM. The EOG in rheumatoid arthritis. Acta Ophthalmol (Copenh) 1983;61:831-7.
25. Gouras P, Gunkel R. The EOG in chloroquine and other retinopathies. Arch Ophtalmol 1963;70:91-100.
26. Mazzuca SA, Yung R, Brandt KD, et al. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol 1994;21:59-63.
27. Easterbrook M. Current concepts in monitoring patients on antimalarials. Aust NZ J Ophthalmol 1998;26:101-3.
28. Arden G, Gunduz K, Perry S. Color vision testing with a computer graphics system:preliminary results. Doc Ophthalmol 1988;69:167-74.
29. Gunduz K, Arden GB, Perry S, et al. Color vision defects in ocular hypertension and glaucoma. Quantification with a computer-driven color television system. Arch Ophthalmol 1988;106:929-35.
30. Berninger T, Drobner B, Hogg C, et al. [Color vision in relation to age:a study of normal values.] Klin Monatsbl Augenheilkd 1999;215:37-42.
31. Nozik RA, Weinstock FJ, Vignos PJ. OcuLar complications of chloroquine. A series and case presentation with a simple method for early detection of retinopathy. Am J Ophthalmol 1964;58:774-8.
32. Niemeyer G, Fruh B. [Examination strategies in the diagnosis of drug-induced retinal damage.] Klin Monatsbl Augenheilkd 1989;194:355-8.
33. Carr RE, Gouras P, Gunkel RD. Chloroquine retinopathy. Early detection by retinal threshold test. Arch Ophthalmol 1966;75:171-8.
34. Marmor MF, Zrenner E. Standard for clinicaL electro-oculography. International Society for Clinical Electrophysioiogy of Vision. Doc Ophthalmol 1993;85:115-24.
35. Henkind P, Carr RE, Siegel IM. Early chloroquine retinopathy:clinical and functional findings. Arch Ophtalmol 1964;71:157-65.
36. Arden GB, Kelsey JH. J Physiol 1962;161:189;205.
37. Arden GB, Friedmann AI, Kolb H. Anticipation of chloroquine retinopathy. Lancet 1962;1:1164-65.
38. Graniewski-Wijnands HS, van Lith GH, Vijfvinkel-Bruinenga S. Ophthalmological examination of patients taking chloroquine. Doc Ophthalmol 1979;48:231-4.
39. Van Lith GH, Mak GT, Wijnands H. Clinical importance of the electro-oculogram with special reference to the chloroquine retinopathy. Bibl Ophthalmol 1976:2-9.
40. Reijmer CN, Tijssen JG, Kok GA, et al. Interpretation of the electro-oculogram of patients taking chloroquine. Doc Ophthalmol 1979;48:273-6.
41. Bishara SA, Matamoros N. Evaluation of several tests in screening for chloroquine maculopathy. Eye 1989;3(Pt 6):777-82.
42. Bernstein HN. Chloroquine ocular toxicity. Surv Ophthalmol 1967;12:415-47.
43. Infante R, Martin DA, Heckenlively JR. Hydroxychloroquine and retinal toxicity. Doc Ophthalmol Proc Ser 1983;37:121-6.
44. Cursiefen C, Grunert U, Junemann A. [Chloroquine-induced bull's eye maculopathy without electrophysiologic changes.] Klin Monatsbl Augenheilkd 1997;210:400-1.
45. Kellner U, Kraus H, Foerster MH. Multifocal ERG in chloroquine retinopathy:regional variance of retinal dysfunction. Graefes Arch Clin Exp Ophthalmol 2000;238:94-7.
46. Wolfelschneider P, Kohen L, Wiedemann P. [Maculopathy in long-term chloroquine therapy.] Ophthalmologe 1998;95:186-7.
47. Okun E, Gouras P, Bernstein HN, et al. Chloroquine retinopathy:a report of eight cases with ERG and dark-adaptation findings. Arch Ophtalmol 1963;58:774-8.
48. Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol (Copenh) 1966;44:335-48.
49. Percival SP, Meanock I. Chloroquine:ophthalmological safety, and clinical assessment in rheumatoid arthritis. Br Med J 1968;3:579-84.
50. Bartel PR, Roux P, Robinson E, et al. Visual function and long-term chloroquine treatment. S Afr Med J 1994;84:32-4.
51. Jaeger W. [Acquired colour-vision-deficiencies caused by side-effects of pharmacotherapy (author's transl).] Klin Monatsbl Augenheilkd 1977;170:453-60.
52. Grutzner P. Acquired color vision defects secondary to retinal drug toxicity. Ophthalmologica 1969;158(Suppl):592-604.
53. Feichtner JJ, Berry AJ, Simkin PA. Vision and taste deficits in rheumatoid arthritis. Arthritis Rheum 1980;23:672.
54. Fristrom B, Lundh BL. Colour contrast sensitivity in cataract and pseudophakia. Acta Ophthalmol Scand 2000;78:506-11.
55. Arden GB, Hall MJ. Does occupational exposure to argon laser radiation decrease colour contrast sensitivity in UK ophthalmologists? Eye 1995;9(Pt 6):686-96.
56. Francois J, Maudgal MC. Experimental chloroquine keratopathy. Am J Ophthalmol 1965;60:459-64.
57. Tobin DR, Krohel G, Rynes RI. Hydroxychloroquine. Seven-year experience. Arch Ophthalmol 1982;100:81-3.
58. Mills PV, Beck M, Power BJ. Assessment of the retinal toxicity of hydroxychloroquine. Trans Ophthalmol Soc UK 1981;101:109-13.
59. Easterbrook M. The ocular safety of hydroxychloroquine. Sem Arthritis Rheum 1993;23:62-7.
60. Percival SP, Behrman J. Ophthalmological safety of chloroquine. Br J Ophthalmol 1969;53:101-9.
61. Potts AM. Further studies concerning the accumulation of polycyclic compounds on uveal melanin. Invest Ophthalmol 1964;3:399.
62. Gonasun LM, Potts AM. In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. Invest Ophthalmol 1974;13:107-15.
63. Leblanc B, Jezequel S, Davies T, et al. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 1998;28:124-32.
64. Francois J, Maudgal MC. Experimental chloroquine retinopathy. Ophthalmologica 1964;148:442-52.
65. Gregory MH, Rutty DA, Wood RD. Differences in the retinotoxic action of chloroquine and phenothiazine derivatives. J Pathol 1970;102:139-50.
66. Legros J, Rosner I. [Electroretinographic modifications in albino rats after chronic administration of toxic doses of hydroxychloroquine and desethylhydroxychloroquine.] Arch Ophtalmol Rev Gen Ophtalmol 1971;31:165-80.
67. Kuhn H, Keller P, Kovacs E, et al. Lack of correlation between melanin affinity and retinopathy in mice and cats treated with chloroquine or flunitrazepam. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1981;216:177-90.
68. Ivanina TA, Zueva MV, Lebedevo MN, et al. Ultrastructural alterations in rat and cat retina and pigment epithelium induced by chloroquine. Graefes Arch Clin Exp Ophthalmol 1983;220:32-8.
69. Ramsey MS, Fine BS. Chloroquine toxicity in the human eye. Histopathologic observations by electron microscopy. Am J Ophthalmol 1972;73:229-35.
70. Rosenthal AR, Kolb H, Bergsma D, et al. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17:1158-75.
71. Hodgkinson BJ, Kolb H. A preliminary study of the effect of chloroquine on the rat retina. Arch Ophthalmol 1970;84:509-15.
72. Lüllmann-Rauch R, ed. Lipoidosis of the retina due to cationic amphiphilic drugs, rat. Berlin: Springer-Verlag, 1991.
73. Meier-Ruge W, Cerletti A. Zur experimentellen Pathologie der Phenothiazin-Retinopathie. Ophthalmologica 1966;151:512-33.
74. Tanenbaum L, Tuffanelli DL. Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine. Arch Dermatol 1980;116:587-91.
75. Duncker G, Bredehorn T. Chloroquine-induced lipidosis in the rat retina:a functional and morphological changes after withdrawal of the drug. Graefes Arch Clin Exp Ophthalmol 1996;234:378-81.
76. Duncker G, Schmiederer M, Bredehorn T. Chloroquine-induced lipidosis in the rat retina:a functional and morphological study. Ophthalmologica 1995;209:79-83.
77. Arden GB. Comparison of new psychophysics and perimetry with electrophysiological techniques in the diagnosis of glaucoma. Curr Opin Ophthalmol 1993;4:14-21.
78. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983;75:40-5.